Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets' Virtual Global Healthcare Conference

Business Wire May 15, 2020

Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights

Business Wire May 14, 2020

Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020

Business Wire May 7, 2020

Aurinia Appoints Joe Miller as Chief Financial Officer

Business Wire April 27, 2020

Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors

Business Wire April 20, 2020

Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings

Business Wire March 18, 2020

Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland

Business Wire March 17, 2020

Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis

Business Wire March 16, 2020

Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative

Business Wire March 12, 2020

Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

Business Wire March 5, 2020

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020

Business Wire March 3, 2020

Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team

Business Wire February 25, 2020

Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Business Wire February 21, 2020

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Common Shares

Business Wire December 12, 2019

Aurinia Prices US$166.7 Million Public Offering of Common Shares

Business Wire December 9, 2019

IIROC Trade Resumption - AUP

Canada NewsWire December 5, 2019

IIROC Trading Halt - AUP

Canada NewsWire December 4, 2019

Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

Business Wire December 4, 2019

Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference

Business Wire December 3, 2019

Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

Business Wire November 14, 2019